➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,300,229

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,300,229 protect, and when does it expire?

Patent 10,300,229 protects XHANCE and is included in one NDA.

This patent has twenty-four patent family members in sixteen countries.

Summary for Patent: 10,300,229
Title:Nasal delivery devices
Abstract: A nasal delivery device for and method of delivering substance to a nasal airway of a subject, the delivery device comprising: a nosepiece (117) for fitting to a nasal cavity of a subject; a mouthpiece (119) into which the subject in use exhales; a delivery unit, which comprises an actuation part which is manually displaceable to actuate the delivery unit to deliver substance from the nosepiece; and a valve assembly (127) which is fluidly connected to the nosepiece and the mouthpiece, wherein the valve assembly comprises a body element (128) and a valve element (131) which is movably disposed to the body element between closed and open configurations by manual displacement of the actuation part of the delivery unit to provide for an air flow through the nosepiece simultaneously with delivery of substance.
Inventor(s): Djupesland; Per Gisle (Oslo, NO), Leclerc; Michael (Cranston, RI), Mahmoud; Ramy A. (Skillman, NJ), Siwinski; Shane (Providence, RI), Gordon; Joseph (Mansfield, MA), Fisk; Justin (Providence, RI)
Assignee: OptiNose AS (Oslo, NO)
Application Number:14/380,827
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 10,300,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes   Start Trial   Start Trial Y METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,300,229

PCT Information
PCT FiledFebruary 25, 2013PCT Application Number:PCT/EP2013/053746
PCT Publication Date:August 29, 2013PCT Publication Number: WO2013/124491

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.